학술논문
Syndecans and diabetic complications: A narrative review.
Document Type
Academic Journal
Author
Rajabloo Y; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Saberi-Karimian M; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran; Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: saberikm@mums.ac.ir.; Soflaei SS; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.; Ferns GA; Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.; Ghayour-Mobarhan M; International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.
Source
Publisher: Elsevier Country of Publication: United States NLM ID: 0370506 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-2990 (Electronic) Linking ISSN: 00029629 NLM ISO Abbreviation: Am J Med Sci Subsets: MEDLINE
Subject
Language
English
Abstract
Syndecan (SDC) is a member of the heparan sulfate proteoglycan (HSPG) family. It appears to play a role in the aetiology of diabetic complications, with decreased levels of SDCs being reported in the kidney, retina, and cardiac muscle in models of diabetes mellitus (DM). The reduced levels of SDCs may play an important role in the development of albuminuria in DM. Some studies have provided the evidence supporting the mechanisms underlying the role of SDCs in DM. However, SDCs and the molecular mechanisms involved are complex and need to be further elucidated. This review focuses on the underlying molecular mechanisms of SDCs that are involved in the development and progression of the complications of DM, which may help in developing new strategies to prevent and treat these complications.
Competing Interests: Conflicts of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.)
Competing Interests: Conflicts of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.)